Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.76 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.76 |
| ▸ | ITGAL | P20701 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | HTR1A | P08908 | 3/20 | 0.69 |
| ▸ | DRD2 | P14416 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | FYN | P06241 | 2/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.69 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.69 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7342890 | 0.99 | ITGB2 (0.74) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Chlorproethazine SCHEMBL29818123 | 0.92 | CYP1A2 (0.77) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Chlorproethazine SCHEMBL149201 | 0.92 | CYP1A2 (0.77) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Chlorproethazine SCHEMBL9724486 | 0.91 | LMNA (0.78) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Chlorproethazine SCHEMBL1648952 | 0.90 | CYP1A2 (0.74) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Diethazine SCHEMBL142924 | 0.87 | POLB (0.83) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Diethazine SCHEMBL30592079 | 0.87 | POLB (0.83) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Cholrphenethazine SCHEMBL3456873 | 0.86 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| Diethazine SCHEMBL142381 | 0.86 | POLB (0.81) | ITGB2ICAM1ITGALCYP1A2CYP2D6 | |
| SCHEMBL7347822 | 0.86 | ITGB2 (0.60) | ITGB2ICAM1ITGALCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250288591-A1 | TRIMEPRAZINE FOR USE IN TREATING TRIGEMINAL NEURALGIA AND FOR REDUCING PAIN RELATED THERETO | UNDAUNTED BIO, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250134903-A1 | COMPOSITIONS AND METHODS FOR TREATING PAIN | UNDAUNTED BIO, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250082647-A1 | SPECIFIC DOSAGE OF PHENOTHIAZINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF ALZHEIMER'S DEMENTIA | IMMUNGENETICS AG (DE) | 2025-03-13 | — | — | US | disclosed |
| US-20240277756-A1 | SILICON PARTICLES FOR HYDROGEN RELEASE | NACAMED AS (NO) | 2024-08-22 | — | — | US | disclosed |
| CN-118510519-A | Specific doses of phenothiazine compounds for use in the treatment or prevention of Alzheimer's dementia | 免疫基因股份公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240189234-A1 | SILICON PARTICLES FOR DRUG DELIVERY | NACAMED AS (NO) | 2024-06-13 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0737066-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| US-4201725-A | TRISUBSTITUTED METHYL-N-METHYLAMINE, PARKINSON*S DISEASE, ANTISPASMODIC AGENTS | LABAZ (FR) | 1980-05-06 | — | — | US | disclosed |
| US-4057644-A | PARKINSON'S DISEASE | LABAZ (FR) | 1977-11-08 | — | — | US | disclosed |
| US-4048334-A | PARKINSON*S DISEASE, NEUROLEPTIC AGENTS | LABAZ (FR) | 1977-09-13 | — | — | US | disclosed |
| US-4026925-A | PARKINSON*S DISEASE | LABAZ (FR) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082647-A1 | SPECIFIC DOSAGE OF PHENOTHIAZINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF ALZHEIMER'S DEMENTIA | PSEN1, PSEN2, APP | ITGB2 2928/4885ICAM1 887/4885ITGAL 2688/4885 |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | ITGB2 4795/4885ICAM1 1916/4885ITGAL 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.